WorkflowResearch & Discovery

Learn · from risk to study

Safety pharmacology core battery: the studies that settle a risk

The core battery covers three organ systems before the first dose in humans. The organ your target assessment is actually worried about is usually not one of them — it belongs to the supplemental studies a cause for concern triggers. This guide maps liabilities to the studies that answer them, and shows how Target Safety Assessment ties each study to the liability it closes.

Updated · 13 min read

See one case, screen by screen →
Watch with transcript →

The safety pharmacology core battery is the set of studies ICH S7A asks for on the cardiovascular, respiratory and central nervous systems before a substance is first given to people. It is fixed, modest and the same for every programme — which is exactly why it rarely answers the question a target safety assessment has raised. A liability in the gut, the immune system or the embryo falls instead to the supplemental studies the guideline reserves for a cause for concern, and that cause for concern is what a good assessment produces. Botminds' Target Safety Assessment writes the second half of that sentence down: each liability carries the study that would settle it, with its species, its weeks, its cost and its owner.

The worked plan on this page is sample data on a fictional target in the product; its study names, weeks and dollar figures belong to that example and are not a price list. Research and regulatory figures are linked where they appear.

What is the safety pharmacology core battery?

It is the minimum set of functional studies, run before people are dosed, on the organ systems whose acute failure is immediately dangerous. ICH S7A names them in one sentence: in this regard, the cardiovascular, respiratory and central nervous systems are usually considered the vital organ systems that should be studied in the core battery (ICH S7A, 2000). The timing is just as explicit — the effects of a test substance on the functions listed in the safety pharmacology core battery should be investigated prior to first administration in humans.

In practice that means three readouts: a cardiovascular study, usually telemetry in a conscious non-rodent with blood pressure, heart rate and the electrocardiogram; a respiratory study, usually plethysmography in a rodent; and a central nervous system observation battery covering motor activity, behaviour, coordination, reflexes and body temperature. They are run on the candidate molecule, late, and they are about the molecule's effects at a given exposure rather than about the biology of the target.

What the core battery does not cover

Everything else, deliberately. The guideline splits the remaining work into two kinds, and the distinction is the one a target assessment needs. Follow-up studies go deeper on the same vital functions: follow-up studies are meant to provide a greater depth of understanding than, or additional knowledge to, that provided by the core battery on vital functions. Supplemental studies go elsewhere entirely, and only on a trigger.

Supplemental studies are meant to evaluate potential adverse pharmacodynamic effects on organ system functions not addressed by the core battery or repeated dose toxicity studies when there is a cause for concern.

ICH S7A, Safety Pharmacology Studies for Human Pharmaceuticals, 2000

The three tiers, and which one answers a target liability

TierWhen it runsWhat it coversWhat it means for a target liability

Core battery

When it runsBefore the first dose in humans

What it coversCardiovascular, respiratory and central nervous system function — the three the guideline calls vital organ systems.

For a target liabilityRun for every substance, whatever the target does. It is a floor, not an answer to your question.

Follow-up studies

When it runsWhen the core battery leaves a vital function unexplained

What it coversGreater depth on the same vital functions the core battery covers.

For a target liabilityTriggered by what the core battery showed, so it arrives late in the programme by design.

Supplemental studies

When it runsWhen there is a cause for concern

What it coversAny organ system the core battery and the repeat-dose work do not address — the renal, gastrointestinal, immune and endocrine systems among them.

For a target liabilityThis is where an on-target liability is usually answered, and the cause for concern is what a target assessment writes down.

The structure ICH S7A sets out. The right-hand column is our reading of what each tier means for a target assessment written before a candidate exists.Source: ICH S7A, 2000

Read that way, the architecture is clear and a little uncomfortable. The studies that happen automatically are about three organ systems chosen for their acute danger, not for their relevance to your target. The studies that would answer an on-target question about the colon, the bone marrow or the fetus happen only if somebody writes down a reason. Nobody is better placed to write that reason than the person assessing the target, and nobody does it later or more expensively than the programme that waits.

Which studies settle an on-target liability?

The ones whose readout would change the score. That sounds circular, and it is the single most useful test to apply, because most proposed studies fail it. A study settles a liability when its result, whichever way it falls, moves the entry — closes it, confirms it, or converts it into something monitorable in the clinic. A study that cannot do that is background work.

Four kinds do most of the settling at target stage. An ex vivo or in vitro functional assay asks whether the degree of inhibition a drug will achieve still leaves the relevant human biology working — the right question when the liability comes from a knockout, which is complete loss. An added endpoint on a study already planned — histology of an organ, a biomarker in serum — buys an answer for the cost of the assay rather than the cost of a study. A readout in a second, better-chosen species answers a question the first species cannot, as a non-rodent cardiac readout does for a rodent QT finding. And a qualified alternative assay can confirm a developmental mechanism without an animal study, where the guideline allows it.

The published target safety assessment of plasmepsin IX/X makes the same move in one line, proposing an early in-life experiment rather than waiting for the regulatory package: an investigative rodent study conducted early in drug discovery would serve as an initial risk assessment of the potential hazards identified (Barber et al., Toxicology Research, 2021). The hazards were identified by reading; the study was chosen to test them.

The mapping: liability, question, study, species, weeks, cost, owner

A de-risking plan is a table, and the discipline is in the columns. Each row starts from a liability that already exists in the register, states the question in a form a result could answer, and then names what it would take. The sample plan below belongs to the fictional target used throughout the product's example; it is short on purpose, because a plan with eleven studies in it is a plan nobody will fund.

One de-risking plan in Target Safety Assessment, from liability to answer

LiabilityThe question a result would answerThe study, and why that speciesWeeks · cost · owner
Weaker response to infectionDoes the degree of inhibition a drug achieves still allow a normal response, or does only complete loss of the target impair it?Ex vivo monocyte infection-response assay — human cells, so the question is asked in the species that matters.3 weeks · $28k · the discovery toxicologist
Worse colitisIs there gut inflammation at the exposures the repeat-dose study already reaches?Colon histology and faecal calprotectin added to the four-week rat study — no new animals, no new study.No added weeks · $7k · the computational biologist
QT prolongation seen in mice onlyDoes the repolarization change survive in a species whose ECG behaves like ours?Dog telemetry in the four-week study with a hERG patch clamp — the rodent is excluded from this question by guideline.4 weeks · $34k · the safety pharmacologist
Sample data on a fictional target, as the product's de-risking plan shows it: three studies, longest four weeks, estimated total $69k, each tied to the liability it answers. The figures belong to this example and are not a price list.

Three properties make such a plan honest. Every row begins with a liability rather than with a study, so nothing is in the plan because it is customary. Every row has an owner who is a person, because a study with no owner is a hope. And the species in the third column is justified in the same cell — chosen because it can answer the question, not because it is the species the next study was going to run in anyway.

What three studies cost in elapsed weeks

Ex vivo infection-response assay3 weeks
Run and read out3 weeks
  • Run and read out3 weeks
Colon histology and calprotectinno added weeks
Inside the four-week study already plannedadded endpoints
  • Inside the four-week study already plannedadded endpoints
Dog telemetry with a hERG patch clamp4 weeks
Run and read out4 weeks
  • Run and read out4 weeks
Sample data on a fictional target. The middle lane is drawn at its host study's length because it adds no weeks of its own: it is two endpoints on a study the programme was running anyway, which is usually the cheapest answer available.

Cause for concern is what a target assessment produces

The phrase in ICH S7A is doing real work. Supplemental studies are not optional extras a cautious team adds; they are the response to a documented reason to be concerned about an organ system the routine package does not address. What counts as such a reason is not defined by the guideline, which is appropriate — it depends on the biology. A ranked list of on-target liabilities, each with the evidence behind it and the organ named, is as close to a written cause for concern as a programme is likely to produce.

This is the argument for doing the assessment at target stage rather than at candidate selection. ICH M3(R2) sets the goals of the non-clinical safety evaluation as characterising toxic effects in four respects — the target organs, how they depend on dose, how they relate to exposure and, where appropriate, whether they reverse (ICH M3(R2), 2009). Every one of those four is cheaper to characterise if the target organs were predicted before the molecule existed. The assessment does not replace the package; it tells the package where to look.

Developmental findings: the knockout, the guideline and the alternative assay

Embryonic lethality in a knockout is one of the most common and most misread findings in target work, so it is worth seeing what the reproductive toxicity guideline actually says. ICH S5(R3) treats an expected developmental effect as a starting position rather than a hypothesis to be tested in animals: for pharmaceuticals that are expected to adversely affect embryo-fetal development based on mechanism of action, pharmacologic class or target biology, it can be appropriate to confirm this activity in a qualified alternative assay(s) (ICH S5(R3), 2020).

The next sentence is the one that saves animals and money: under this scenario, since the pharmaceutical is expected to adversely affect embryo-fetal development, there is no merit in using in vivo EFD studies to attempt to negate a positive alternative assay response. In other words, where the biology says the effect is expected, the work to do is confirmation and management — labelling, contraception requirements, exclusion criteria — not two in vivo studies run in the hope of a different answer. A target assessment that records embryonic lethality with its allele and zygosity, and says plainly that the effect is expected from the mechanism, puts the programme on that path at the start.

The reverse error matters too. A germline knockout removes the gene from conception in every tissue, which is not what an inhibitor given to an adult does. The reading of such a finding, and what a conditional knockout adds, is worked through in the guide to reading knockout phenotypes.

Monitoring in the first trial, where a study cannot settle it

Some liabilities cannot be closed before people are dosed, either because no animal model reproduces the biology or because the effect is subjective. For those the honest output is not a study but a monitoring line: a measurement in the first clinical trial, a stopping rule, an exclusion criterion. Whether a risk is monitorable is itself part of its score — a serious effect that announces itself on a weekly blood count is a different risk from the same effect arriving silently.

Writing the monitoring line at target stage has one practical advantage over writing it later: it can be carried straight into the protocol and the investigator's brochure by the people who will run the trial, with the evidence that produced it attached. In the sample assessment the monitoring section sits beneath the de-risking plan and is drawn from the same register, so every monitored item traces back to a liability someone scored.

A liability with a named study, against one left to the clinic

Named studyMonitor in the clinic
What the entry says

Named study: The question, the study that answers it, the species and why, the weeks, the cost, the owner.

Monitor in the clinic: The measurement, its frequency, the stopping rule, and who is excluded.

When it is the right answer

Named study: An animal or in vitro readout exists that would move the score either way.

Monitor in the clinic: No model reproduces the biology, or the effect is detectable and reversible in people under observation.

When it is the wrong answer

Named study: The study cannot reach clinical exposures, or its result would not change anything.

Monitor in the clinic: It is chosen because the study was inconvenient — which converts a question into a risk carried by the first volunteers.

What it costs

Named study: Weeks and money, spent before the committee decides.

Monitor in the clinic: Little at the time, and a protocol amendment later if the finding appears.

Both are legitimate outputs of an assessment; only one of them is legitimate as a default. Target Safety Assessment keeps monitorability as part of each liability's score rather than as a separate decision.

What a de-risking plan costs, and how to choose what to fund

Against the cost of development, a plan of this size is a rounding error. The median capitalised investment to bring a new drug to market has been estimated at $985.3 million, with a 95% confidence interval of $683.6 million to $1,228.9 million, after accounting for the cost of failed trials (Wouters, McKee and Luyten, JAMA, 2020). A plan whose three studies cost tens of thousands of dollars and whose longest runs four weeks in parallel with chemistry is not a budget decision; it is a sequencing decision.

The sequencing argument is supported by what animal studies actually catch and when. In the classic multi-company survey of concordance between animal and human toxicity, where animal models in one or more species identified a toxicity that was also seen in people, 94% were first observed in studies of 1 month or less in duration (Olson et al., 2000). Most of the predictive value of animal work arrives early. A short, well-aimed study near the start is doing the same job as a long one later, sooner and for less.

Three numbers behind a de-risking plan's economics

3studies

in the sample plan, longest four weeks, running in parallel with chemistry

94%

of animal findings concordant with human toxicity were first seen in studies of one month or less

$985.3m

median capitalised investment estimated to bring one new drug to market, after the cost of failed trials

The first figure is sample data on a fictional target in the product; the second is from the Olson et al. concordance survey (2000); the third from Wouters, McKee and Luyten in JAMA (2020), base-case estimate, 95% CI $683.6m–$1,228.9m.Source: Olson et al., Regul Toxicol Pharmacol 2000; Wouters et al., JAMA 2020

What to fund, then, follows three rules rather than a formula. Fund the studies that would change a decision the committee is about to take. Prefer an added endpoint on a study already planned to a new study, every time it will do. And where two studies would answer the same question, choose the one in the species that can answer it — a cheap study in the wrong animal is the most expensive line in any plan.

What every study in a de-risking plan has to state before it is funded

  1. The liability it answers, by name

    Written as the register writes it, so the result closes a specific entry rather than producing general reassurance.

  2. The question, in a form a result can answer

    Not "characterise the gut effect" but "is there histological inflammation at the exposures the four-week study reaches".

  3. The species, with the reason

    Chosen because it can answer the question. Where a guideline excludes a species for an endpoint, say so in the cell.

  4. What each outcome would mean

    What a negative result closes and what a positive result triggers — decided before the study runs, not after.

  5. Elapsed weeks, and whether it sits on the critical path

    An added endpoint on a planned study often costs no weeks at all; that is the difference between a plan and a delay.

  6. Cost and a named owner

    A person who will run it and report it. A study with a function rather than a person attached does not get done.

The six fields behind each row of a fundable plan. In the product the agents propose the studies and the toxicologist decides which go in; the proposal is never the decision.

How Target Safety Assessment ties each study to its liability

The risk scorer proposes de-risking studies alongside the probability and impact it suggests for each liability, and its limit is stated rather than implied: it proposes, and a toxicologist accepts, re-scores or dismisses. Each proposed study arrives attached to the entry it answers, with weeks, cost and an owner, and switching one on puts it in the plan with that link intact. The plan's header counts what is in it and what the longest study costs in elapsed time, because that is the number a project leader actually needs.

The de-risking plan: three studies, each tied to the liability it answers

A de-risking plan screen for a fictional target. Three summary cards read three studies of three in the plan, longest study four weeks running in parallel with chemistry, and estimated cost sixty-nine thousand dollars of external and internal work. A table below lists each study with a toggle, what it measures, the liability it answers, its weeks, its cost and its owner: an ex vivo monocyte infection-response assay at three weeks and twenty-eight thousand dollars, colon histology and calprotectin inside the four-week rat study at seven thousand dollars with no added weeks, and dog telemetry with a hERG patch clamp at four weeks and thirty-four thousand dollars. A monitoring section for the first clinical trial follows, drawn from the liability register.
Sample data on a fictional target. The liability chip in the Answers column is the link that makes the plan readable backwards: every study exists because an entry in the register asked for it.

The report carries the same structure into the document. Monitoring and the de-risking plan is one of the sections every assessment contains, written from the register rather than retyped, and species relevance and study design is an optional section, switched on in the sample settings. What the report looks like, and who signs it, is set out in the guide to running the assessment by hand, outsourced or with agents.

The plan arrives in the report as a section, not as an attachment

A draft report for a fictional target in a house template. A section list on the left shows eight numbered sections — summary, target and pathway, human genetics, animal models, expression, same-mechanism drugs, liability register, and monitoring and de-risking plan — marked as drafted with every statement cited, with buttons to export to Word or send to the regulatory summary. The document pane shows the summary recommending a de-risking plan, followed by target and pathway, human genetics and animal models sections, each statement carrying a numbered citation that opens its source passage.
Sample data on a fictional target. The monitoring and de-risking section is written from the same register the plan is built from, so a study cannot appear in the report without the liability that justified it.

The test of a plan is whether a reviewer can read it backwards: from a study, to the question, to the liability, to the passage that produced it. To see the three studies against the register they came from, start from Target Safety Assessment.

Questions people ask

What is the safety pharmacology core battery?

It is the set of functional studies ICH S7A asks for on the cardiovascular, respiratory and central nervous systems — the organ systems it calls vital — investigated before a substance is first given to humans. It is run on the candidate molecule and is the same for every programme, so it is a floor rather than an answer to a target-specific question.

What is a supplemental safety pharmacology study?

It is a study of an organ system the core battery and the repeat-dose toxicity studies do not address — renal, gastrointestinal, immune, endocrine and others — run when there is a cause for concern. That trigger is why a documented on-target liability matters: it is the written reason that makes the study justifiable rather than discretionary.

Do you need an embryo-fetal study if the knockout is lethal?

Not necessarily in the way programmes assume. ICH S5(R3) says that where a pharmaceutical is expected to affect embryo-fetal development from its mechanism, class or target biology, confirming that activity in a qualified alternative assay can be appropriate — and that there is no merit in running in vivo studies to attempt to negate a positive alternative assay response. The work shifts from proving the effect to managing it.

When must the core battery be done?

Before the first administration in humans, as ICH S7A states directly. Follow-up studies are triggered by what the core battery shows and so come later; supplemental studies are triggered by a cause for concern and can be run much earlier, which is why a target-stage liability can buy an answer long before the regulatory package is assembled.

How much does a de-risking plan cost?

It depends entirely on what is in it, and the useful comparison is not with other studies but with the development programme: the median capitalised investment to bring a drug to market has been estimated at $985.3 million. In the sample plan used here three studies total $69,000 with the longest running four weeks in parallel with chemistry — figures that belong to that fictional example rather than to any price list.

Who owns each study in a de-risking plan?

A named person, not a function. In the sample plan the ex vivo infection assay sits with the discovery toxicologist, the added gut endpoints with the computational biologist and the cardiac work with the safety pharmacologist. The reason to insist on a name is practical: the plan is reviewed weeks later, and an unowned row is the one that has not moved.

Target Safety Assessment.
See it on your own files.

An agentic solution from Botminds. A body map of one target's on-target risks, organ by organ, from knockout mice, human carriers, expression and same-mechanism drugs, scored, cited and signed by a toxicologist. Book a demo, or explore how it works.